Dow Wolff to work on formulation with pharma customers

Published: 19-Oct-2009
Ingredients

Dow Wolff Cellulosics (DWC) is intensifying its focus on the formulation and ingredient delivery needs of the Pharma market, offering formulation know-how to help customers innovate and differentiate in highly-regulated markets.


Dow Wolff Cellulosics (DWC) is intensifying its focus on the formulation and ingredient delivery needs of the Pharma market, offering formulation know-how to help customers innovate and differentiate in highly-regulated markets.

DWC's Pharma division says it will work closely with formulators and manufacturers not only to meet existing needs, but also to drive innovation and new technologies that address emerging and future formulation and delivery challenges.

Our intention is to forge a new level of relationship with drug formulators and manufacturers, to see how they can use our expertise and know-how to address specific challenges around the delivery mechanisms of the future,. said Lucrece Foufopoulos, global marketing director of DWC.

Dow claims to hold, between its various business units, five of the top 10 excipient technologies. The Pharma division has already developed three optimised solutions for today's pharmaceutical manufacturing technologies.

Methocel Premium Direct Compression grade hypromellose polymers have been developed to achieve the production economies of direct compression while assuring the multi-functional performance customers expect from this excipient family.

The company is also offering Polyox water-soluble resins, Ethocel ethylcellulose ethers and Methocel cellulose ethers developed for Hot Melt Extrusion (HME) processing, which reduces processing time and cost. The products achieve better content uniformity, which improves the bio-availability of poorly soluble drugs and eliminates the need for aqueous processing.

Its third solution, Methocel Premium Controlled Release products are specifically tailored to use in controlled release drug delivery systems that increase treatment success rates and improve cost effectiveness. These products have been manufactured for enhanced lot-to-lot consistency in chemical and physical properties that impact drug release performance, resulting in fast development of robust formulations.

The company says the cellulosics and their derivatives are produced from renewable raw materials, mainly wood pulp and cotton, sourced primarily from suppliers that implement certified sustainable forestry practices.

  • Companies:
  • Dow Chemical Company
See more

You may also like

Ingredients

Dow to increase capacity for solid CARBOWAX SENTRY polyethylene glycols to meet global demand

Read more
Dow, a leading supplier of polyethylene glycols (PEGs), today announced a low-capital, high-ROIC investment in a new congealer to increase its production capacity for CARBOWAX SENTRY polyethylene glycols in solid powder and granular form

Trending Articles

  1. FDA makes groundbreaking decision to waive clinical efficiency studies for monoclonal antibody biosimilars The University of Illinois secured the first-ever FDA acceptance to waive clinical efficiency studies (CESs) for the biological drugs
  2. Rousselot Rousselot is a global leader of gelatin and collagen-based solutions, serving the food, health & nutrition, biomedical, and pharmaceutical sectors. With our advanced Science & Innovation team, we unlock the secrets of the collagen molecule to create products that meet the highest standards of safety and quality. Through our state-of-the-art operations and extensive technical and formulation expertise, we help our customers achieve their goals, create world-class products, and we “Reach further together”. Rousselot is Darling’s Ingredients Health Brand.
  3. Debunking the myths of HPMC adoption Adopting new products, formulations and ways of working can be a challenge for industries as regulated as pharmaceuticals, writes Dr Subhashis Chakraborty, General Manager, Head of Global Product Management, at ACG Capsules
  4. Lubrizol to showcase game-changing excipients and nutraceutical ingredients at CPHI Frankfurt Lubrizol partners with pharmaceutical and nutraceutical companies to develop innovative solutions that improve patient outcomes and offer consumer benefits
  5. Evonik increases plant-derived cholesterol supply The ingredient is used in the manufacture of mRNA vaccines and gene therapies

Upcoming event

Enhancing probiotic stability through smarter formulation and packaging strategies

18 September 2025 | Virtual See all

You may also like

Ingredients

Dow to increase capacity for solid CARBOWAX SENTRY polyethylene glycols to meet global demand

Dow, a leading supplier of polyethylene glycols (PEGs), today announced a low-capital, high-ROIC investment in a new congealer to increase its production capacity for CARBOWAX SENTRY polyethylene glycols in solid powder and granular form
Ingredients

Dow and Colorcon broaden the scope of their Controlled Release Alliance

From January next year the partnership will include Dow's advanced technology based excipients
You need to be a subscriber to read this article.
Click here to find out more.
Ingredients

Ingredients see a drive for more science

The need for greater solubility and bioavailability of new medicines, as well as increasing manufacturing efficiencies are driving developments in ingredients. Susan Birks reports on the latest trends
Ingredients

CPHI: Dow introduces solvent-free technology for coating barrier membranes

Ethocel HP enables faster tablet coating times, increasing drug production productivity yields
Ingredients

LIVE FROM CPHI: Dow Pharma & Food and Colorcon to have commercial availability of Methocel DC2 by year end

Offers improved process control for matrix tablet production
You need to be a subscriber to read this article.
Click here to find out more.
Media

Good growth for ingredients, but costs could rise

In the fast growing API and excipient markets, solubility, taste-masking and functionality are the focus. Susan Birks looks at current trends and issues on the horizon
You need to be a subscriber to read this article.
Click here to find out more.
Ingredients

Improving the taste of paediatric medicines

Ion exchange excipients are well characterised and have a favourable safety profile in oral formulations. Amie Gehris and Jon Fisher, Dow Chemical Co, look at their use in overcoming formulation challenges for oral paediatric medications
Subscribe now